PKA/eNOS通路在缺血性组织疾病治疗性血管再生中的作用

Emerging role of PKA/eNOS pathway in therapeutic angiogenesis for ischaemic tissue diseases

2012-07-16 12:14点击：3次发表评论

作者：Shyamal C. Bir,, Yan Xiong, Christopher G. Kevil,

期刊： 《CARDIOVASC RES 》2012年7月1期95卷

Abstract

Although an abundant amount of research has been devoted to the study of angiogenesis, its precise mechanisms are incompletely understood. Numerous clinical trials focused on therapeutic angiogenesis for the treatment of tissue ischaemia have not been as successful as those of preclinical studies. Thus, additional studies are needed to better understand critical molecular mechanisms regulating ischaemic neovascularization to identify novel therapeutic agents. Nitric oxide (NO) plays a central role in ischaemic neovascularization through the generation of cyclic guanosine monophosphate (cGMP) and the activation of several other signalling responses. Accumulated evidence suggests that endothelial protein kinase A/endothelial NO synthase (PKA/eNOS) signalling may play an important role in ischaemic disorders by promoting neovascularization. This review highlights recent advances in the role of the PKA/eNOS and NO-cGMP-kinase cascade pathway in ischaemic neovascularization. We also discuss molecular relationships of PKA/eNOS with other angiogenic pathways and explore the possibility of activation of the NO/nitrite endocrine system as potential therapeutic targets for ischaemic angiogenesis.

Key words

PKA
eNOS
Nitric oxide
Nitrite
Vascular remodelling

Previous SectionNext Section

1. Introduction

Ischaemic vascular diseases remain a leading cause of mortality and morbidity worldwide. Despite significant advances in medical and surgical intervention, the burden of these illnesses remains high. Restoration of blood flow to ischaemic organs is vital to prevent tissue death after arterial occlusion. As a strategy for the treatment of acute and chronic ischaemia, therapeutic angiogenesis evolved soon after the discovery of angiogenic growth factors.^1–3 Experimental studies showed initial promise of therapeutic angiogenesis in small animal and selected large animal models.⁴ However, after more than a decade of clinical investigation, none of the larger double-blinded, placebo-controlled trials of angiogenesis therapy in patients with various vascular diseases have demonstrated significant benefits.^5–8 Although the reason for this is complex, the lack of a comprehensive knowledge of biochemical and molecular mechanisms driving angiogenesis is a major obstacle to the development of effective therapeutic approaches.^9,10

Ischaemic neovascularization involves three major processes: angiogenesis, arteriogenesis (collateralization), as well as post-natal vasculogenesis, although the discrete importance of each process remains unclear.^11–13 Angiogenesis, the process of new capillary growth through sprouting from existing small blood vessels, is initiated from the activation of endothelial cells (ECs), followed by proliferation, migration, and tube formation. Ischaemia/hypoxia induces a variety of angiogenic factors that drive the formation of new vessels.¹² Arteriogenesis, including collateralization, refers to the outward growth and remodelling of existing arterioles into larger arteries when a main artery is obstructed. Among the various factors, mechanical forces including circumferential wall tension and shear stress seem to be primarily important for arteriogenesis.^14,15 Post-natal vasculogenesis is a process by which blood vessels are established de novo from endothelial progenitor cells (EPCs) derived from bone marrow (BM).¹⁶ These processes are collectively involved in regulating tissue neovascularization to restore blood perfusion back to the ischaemic region with vasculogenesis playing a complementary role by incorporating EPCs into the endothelium of new vessels (angiogenesis) or the remodelling of arteries (arteriogenesis).^12,17

Mechanistically, ischaemic neovascularization is stimulated by several chemical, physical, and mechanical factors through distinct but partially overlapping cellular and molecular pathways.^11,12 Ischaemia/hypoxia and concurrent acidic pH induce the expression of a set of angiogenic genes including growth factors such as vascular endothelial growth factor (VEGF) and placental growth factor,^1,12,18,19 as well as chemokines such as monocyte chemoattractant protein-1 (MCP-1) and stromal-derived factor 1α (SDF-1α),^19,20 which can drive post-natal vasculogenesis.²¹Mechanical factors such as circumferential wall tension may initiate arteriogenesis via the induction of smooth muscle MCP-1 expression,¹⁵and shear stress signalling involving endothelial adhesion molecule PECAM-1¹⁴ is critical for arteriogenesis. It is noteworthy that inflammatory pathways also participate during ischaemic neovascularization. Together, the stimulation of ischaemic vascular remodelling is dynamic requiring multiple experimental approaches to understand key cellular and molecular events of neovascularization.

Extensive efforts have been made to better understand various intracellular signalling and molecular cascades of ischaemic neovascularization. It is clear that distinct ischaemic factors trigger multiple intracellular signalling pathways that converge into several pathways where endothelial nitric oxide synthase (eNOS)/nitric oxide (NO) is involved. eNOS catalyses the conversion of L-arginine to L-citrulline generating NO that is important for the angiogenic activity of several factors including VEGF.^22–25 Akt/protein kinase B is regarded as a central upstream signalling regulator leading to eNOS activation.⁹ However, experimental evidence indicates that protein kinase A (PKA) is also an important mediator in eNOS activation during ischaemic neovascularization. This is in contrast with controversial roles; PKA may serve during angiogenesis.^26–29 Here, we discuss recent experimental advances of reactive oxygen species (ROS)/NO bioavailability, PKA/eNOS signalling, and NO-mediated cellular responses in ischaemic neovascularization and explore potential therapeutic uses of these targets to modulate ischaemic angiogenesis.

Previous SectionNext Section

2. Neovascularization and NO bioavailability

Angiogenesis, vasculogenesis, and arteriogenesis are three principle events regulating tissue repair and remodelling in acute and chronic vascular diseases as mentioned earlier.³⁰ However, these processes are driven by separate, yet partially overlapping, cellular, and molecular pathways. Experimental studies have identified that angiogenesis and vasculogenesis involve various angiogenic growth factors such as VEGF, fibroblast growth factor (FGF), angiopoietins, platelet-derived growth factors (PDGF), and signalling molecules (e.g. NO), transcription factors, e.g. hypoxia-inducible factor-1 (HIF-1), various integrins, ephrins, and progenitor cells to enhance new blood vessel formation.^12,30–32 On the other hand, mechanical stimuli including oscillatory and steady laminar shear stress, and circumferential and longitudinal wall tension stretch stress regulate cell adhesion molecules and mitogenic factors that stimulate collateral vessel remodelling.^12,30–33 The following sections discuss the effect of NO metabolism and bioavailability during the processes of neovascularization.

2.1 Angiogenesis and NO bioavailability

Endothelium-derived NO plays a pivotal role in the maintenance of vascular tone via triggering smooth muscle relaxation, as well as in other pathophysiological processes, e.g. angiogenic response, of the EC.³⁴ NO induces smooth muscle cell (SMC) relaxation via the cGMP-PKG pathway, inhibiting calcium release through the IP3 receptor, decreasing intracellular calcium concentrations, and altering cytoskeleton organization.³⁵ During ischaemic conditions, NO modulates angiogenesis activity^24,36 through direct interaction of NO via S-nitrosylation of various proteins, including HIF-1.³⁷ Notably, NO production contributes to the angiogenic properties of VEGF in human ECs.³⁸ Evidences suggest that VEGF stimulates the release of NO from cultured human umbilical vein EC (HUVECs) by augmenting eNOS expression and phosphorylation.^39,40Similar effects have been suggested for other factors, e.g. bFGF and substance P.^41,42 Moreover, VEGF- and FGF-induced angiogenesis is blunted by an NOS inhibitor, N-nitro-L-arginine methyl ester (L-NAME) in a rabbit cornea model of angiogenesis.^38,43,44 Likewise, angiogenesis activity can be diminished when NO bioavailability is reduced as evidence indicates that in vitro angiogenic activity is inhibited by oxidized LDL, which is known to decrease NO bioavailability.⁴⁵ Importantly, endothelium-dependent NO-mediated vasodilation and angiogenic response to hind limb ischaemia is blunted in hypercholesterolaemic rabbits.^45,46 Moreover, vascular remodelling during hind limb ischaemia is impaired in eNOS-knockout (KO) mice that cannot be reversed by exogenous VEGF therapy.⁴⁷

Precise mechanisms of NO-mediated angiogenesis are not completely understood, although studies support the hypothesis that NO stimulates both endothelial proliferation and migration.^47–49 The growth-promoting effect of NO is associated with cGMP generation in the cultured endothelium.^50,51 Importantly, NO along with cGMP production further reinforce this response by increasing VEGF and bFGF expression.^50,52,53Studies have also shown that VEGF-induced angiogenesis is inhibited by an sGC inhibitor LY83583^39,43,48,50 and that cGMP production activates kinase cascades including PKG and mitogen-activated protein kinase (MAPK) cascades Ras, Raf1, and ERK.^50,54,55 NO enhances EC migration by stimulating EC podokinesis, enhancing the expression of αvβ3 integrin, and increasing bFGF-mediated dissolution of extracellular matrix.^47,53,56Matrix metalloproteinase (MMP) degradation of matrix is important for vascular remodelling⁵⁷ and stimulates EC migration in part due to the activation of MMP-13 both in vitro and in vivo.⁵⁸ eNOS can also colocalize with membrane type 1-MMP on EC membrane and NO regulates compartmentation, activity, and function of MT1-MMP in ECs, making it an important target for NO regulation of EC migration, tube formation, and angiogenesis.⁵⁹ Conversely, it has been shown that eNOS gene transfer decreases MMP-2 and MMP-9 activities and inhibits smooth muscle migration.⁶⁰ Studies also suggest that NO-dependent peroxynitrite formation also regulates MMPs in different conditions such as in atherosclerotic plaque instability, myocardial injury, and tumour metastasis.^61–64 Therefore, although NO has diverse actions on MMPs, MMP-13 and MT1-MMP activities are required for NO-induced EC migration, tube formation, as well as angiogenesis. In summary, these and other cellular events are significantly influenced by NO production and bioavailability, thus modulating angiogenic activity involving EC proliferation, migration, and matrix remodelling (Figure 1).

View larger version:

In this page
In a new window

Download as PowerPoint Slide

Figure 1

Prototypical angiogenic cytokine signalling pathways invoking endogenous NO production and subsequent kinase cascade activation. VEGF/VEGFR2 binding stimulates AKT/PKA mediated eNOS activation and NO production. NO mediated activation of sGC increases cGMP formation and PKG activity modulating subsequent MAPK cascades Ras, Raf, and ERK1/2 signalling. These events regulate EC proliferation and migration, and extracellular matrix remodelling resulting in angiogenesis.

2.2 Vasculogenesis and NO bioavailability

The BM-derived EPC is the key cell involved in vasculogenesis to restore blood flow in ischaemic tissue. Studies show that EPCs are mobilized from the BM into the systemic circulation, home to ischaemic sites, undergo in situ differentiation, and ultimately participate in the formation of new blood vessels.^16,65,66 This EPC mobilization cascade starts with peripheral ischaemia-induced tissue release of VEGF and subsequent activation of BM stromal NOS, resulting in increased BM NO production.^67,68 Besides this, the absolute number of EPCs in eNOS-KO mice and mice treated with L-NAME is significantly reduced, suggesting an important role of eNOS for basal EPC regulation.⁶⁹ Data also suggest that physical exercise also increases NO bioavailability and the number of EPCs, which is blunted by inhibition or deletion of eNOS.⁷⁰ Similarly, statin-induced NO-mediated EPC recruitment is blocked by treatment withL-NAME.⁷¹ Thus, NO bioavailability is also important for the stimulation of EPC mobilization and recruitment in the ischaemic site results in vasculogenesis.

2.3 Arteriogenesis and NO bioavailability

Although angiogenesis is ischaemia-driven, hypoxia is not required for arteriogenesis.⁷² As such, arteriogenesis activity occurs under normoxic environments far from ischaemic tissue regions.⁷³ Changes in mechanical forces acting on the ECs lining collateral vessels promote required inflammatory signals to start collateral remodelling.⁷⁴ As a form of vessel growth, pathological arteriogenesis may be related to increased shear and stretch forces as a consequence of increased flow through pre-existing collateral arterioles due to an increase in the pressure gradient following occlusion of a major artery.⁷⁵ NO derived from eNOS mediates vasodilation thus decreasing vascular resistance and also facilitates proportional vascular remodelling that controls changes in blood flow.⁷⁶Arteriogenesis activity during ischaemia has been reported to involve a series of different factors including monocyte/macrophage-derived cytokines such as MCP-1, PECAM-1, and VEGF, as well as changes in shear stress of pre-existing collaterals that would activate eNOS acutely to stimulate arteriogenesis via outward vascular remodelling.^74,77 Yu et al.²⁵ showed that EC-derived NO plays a crucial role in arteriogenesis, pericyte recruitment, and stabilization of angiogenic vessels. NO also mediates the angiogenic effect by neuropeptide Y (NPY) in both hind limb ischaemia and chronic myocardial ischaemia models. NPY is evidenced to enhance capillary angiogenesis and collaterization via the activation of eNOS and up-regulation of angiogenic genes such as VEGF and PDGF.^78,79 Moreover, collateral vessel formation and subsequent recovery of blood flow were markedly increased in the ischaemic limb of eNOS transgenic mice.^80,81 In contrast, evidence from literature also demonstrates that NO prevents pro-inflammatory EC differentiation or expression of MCP-1.⁸² NO also inhibits SMC proliferation under certain vascular conditions.⁸³ Despite the above findings, the role of NO during collateral remodelling and arteriogenesis remains poorly understood.

Previous SectionNext Section

3. Relationship of NO and ROS, and their effects on neovascularization

Proper functioning of the endothelium is often linked to the production and bioavailability of NO and regulation of ROS. Both ECs and vascular SMCs are capable of producing ROS from a variety of enzymatic sources. Studies have shown that ROS is produced in different subcellular compartments. NADPH oxidase and eNOS (uncoupled) are cell membrane-bound ROS-generating enzymes.^84,85 Mitochondria are also another major source of ROS production with primary locations of O₂^·⁻production at complexes I and III of the respiratory chain.⁸⁶ Cytosol and peroxisomes involve NADPH oxidase, eNOS, and xanthine oxidase to produce ROS. NADPH oxidase can also be located in the sarcoplasmic reticulum and produce ROS.^87–89 Free radicals have one or more unpaired electrons in their outer orbital, which make them highly unstable and prone to reaction with adjacent molecules by donating, abstracting, or even sharing their outer orbital electron. This can also result in the formation of secondary reactive species that can modify additional targets. An example of this is the reaction of NO with superoxide to form peroxynitrite that is a potent oxidant and nitrating molecule.⁹⁰ Critical detoxification mechanisms exist to regulate the formation of reactive species such as superoxide dismutases (SOD's), and glutathione peroxidases in conjunction with glutathione, thioredoxin, and peroxiredoxins facilitate reactive molecule decomposition to diminish intracellular redox imbalance.

Therefore, it is important that redox reactions having a short half-life be considered during studies of free radical/oxidant mechanisms of vascular disease and therapeutics. ROS can positively or negatively regulate vascular growth and remodelling. Although the exact nature of this relationship remains unknown, physiological or low levels of ROS are required for vascular growth. However, high amounts of ROS may react with various cellular components including the lipid, protein, and DNA resulting in loss of cell integrity, enzyme function, and genomic stability.⁹¹ Physiological levels of ROS from different sources under physiological conditions act as intracellular second messengers modulating proangiogenic signalling pathways affecting EC proliferation, EC barrier function, vasorelaxation, vascular remodelling, and VEGF-A signalling as well as post-natal vasculogenesis.^92,93 NADPH oxidase has been shown to play a role in the regulation of angiogenic growth factors such as VEGF and VEGF-induced angiogenesis in otherwise young, healthy animals.⁹⁴ Tojo et al.⁹⁵ further showed that ischaemic hind limb neovascularization is significantly impaired in gp91 phox-KO mice, possibly due to a reduction in production from inflammatory and local vascular cells. Hypoxia-induced production of NADPH oxidase can be inhibited with pharmacological inhibitors resulting in diminished ROS formation, decreased VEGF production, blunted Akt and ERK1/2 activation, and subsequently reduced angiogenesis.^96,97 It is also reported that ROS controls the VEGF expression by the activation of AP-1 transcription factor through subunit junB.⁹⁸ ROS overproduction in mitochondria has been also linked to a pro-angiogenic cellular status. Inhibiting ROS production by mitochondria complex 1 using rotenone was found to inhibit the expression of VEGF, in a tumour model, stopping angiogenesis in vivo and in vitro.⁹⁷ Conversely, excessive production of vascular superoxide contributes to impairment of endothelium-dependent vasorelaxation due to decreased NO bioavailability. Increased levels of peroxynitrite reduce tetrahydrobiopterin (BH₄) production and also a reduction in the BH₄-producing enzyme, guanosine triphosphate cyclohydrolase expression, contributing to eNOS uncoupling.^99,100Specifically, peroxynitrite rapidly oxidizes active BH₄ to inactive dihydrobiopterin (BH₂), further leading to eNOS uncoupling.¹⁰¹ Moreover, peroxynitrite causes eNOS uncoupling through the disruption of zinc–thiolate cluster of eNOS by releasing zinc from the cluster and forming disulfide bonds between the monomers.¹⁰² Increased oxidation of BH₄may be responsible for some of the cellular pathophysiological effects of enhanced ROS formation in the endothelium during vascular disease.^101,103 However, the precise amount and species specificity of ROS involved during EC dysfunction in vivo are not completely understood nor is it clear what concentration of ROS impairs neovascularization by inducing endothelial dysfunction and apoptosis resulting from reduced NO bioavailability.^92,93

Reduced NO bioavailability is unable to redirect blood flow through pre-existing collaterals due to impaired vasodilation, further reducing shear-mediated remodelling of collaterals thus reducing tissue blood flow. This reduction in blood flow reduces shear stress-dependent eNOS activation and subsequent NO release retarding further growth of collaterals, flow-mediated angiogenesis, and remodelling of angiogenic sprouting in the lower limb.^80,81 Although inflammatory signals may be needed for the start of the collateral growth, chronic inflammation is detrimental to vascular remodelling.⁷⁴ Excess amount of ROS generated during inflammation or ischaemic response may inhibit vascular growth and remodelling by inducing endothelial dysfunction including impaired vasomotor function, the recruitment of monocytes, diminished endothelial barrier function, and enhanced thrombosis.^104,105 In pathological conditions such as diabetes, atherosclerosis, hypertension, cardiac failure, and ischaemia reperfusion injury, excessive ROS generation or decreased NO bioavailability mediates EC dysfunction, cell proliferation, migration, inflammation, extracellular matrix deposition, apoptosis, fibrosis, cardiovascular growth, and remodelling.^106,107 From the above discussion, it is clear that increased ROS and subsequent reduced NO bioavailability impair vascular growth and remodelling, which highlights important targets for therapeutic angiogenesis in ischaemic myocardial infarction, peripheral vascular disease, as well as stroke. Significant advances have been made with respect to quantitative analytical methods to detect specific ROS and NO species that must be employed in future studies to better understand the relationship between ROS levels and stimulation of vascular remodelling in conjunction with NO bioavailability.

Previous SectionNext Section

4. ROS, diabetes, and atherosclerosis

Studies indicate that eNOS function is impaired in diabetes and atherosclerosis as a result of increased vascular generation of ROS and reduced NO bioavailability in diabetic and hypercholesterolaemia patients and animal models.^108–110 Hypercholesterolaemia, hyperglycaemia, oxidized atherogenic lipoproteins, and advanced glycation end products are all linked to altered oxidative stress that can augment their production. High levels of glucose and lipid increase NADPH oxidase activity and impair the activities of mitochondrial complex enzymes leading to the formation of excessive ROS during diabetes and atherosclerosis.¹⁰⁷ Human atherosclerotic samples show a greater mitochondrial DNA damage than non-atherosclerotic samples highlighting increased ROS production in atherosclerosis. Moreover, mitochondrial damage precedes the development of atherosclerosis in apolipoprotein E-KO mice with or without heterozygous deficiency of SOD.^111,112 Thus, overproduction of ROS is associated with the activation of a variety of pro-inflammatory signals and inactivates anti-atherogenic enzymes such as eNOS and prostacycline synthase,¹¹³ resulting in decreased NO bioavailability in disease states. Therefore, excessive ROS production impairs ischaemic vascular remodelling and blockade of NADPH oxidase activity or scavenging of ROS restores post-ischaemic neovascularization in diabetes and atherosclerosis.¹¹⁴ ROS also impairs ischaemic neovascularization in hypercholesterolaemic animal models or human patients.^114,115 In these reports, the authors showed that both the macrovascular (blood flow recovery) and microvascular (capillary density) levels of ischaemia-induced neovascularization were significantly impaired with high cholesterol diet-induced hypercholesterolaemic mice with hind limb ischaemia. NADPH oxidase expression and oxidative stress was increased, but eNOS activity was decreased in ischaemic tissues of these hypercholesterolaemic mice.¹¹⁴ In contrast, NADPH oxidase expression, oxidative stress, and eNOS activity were not affected in NADPH oxidase-deficient hypercholesterolaemic mice that displayed augmented ischaemia-induced neovascularization during hypercholesterolaemia. Therefore, NADPH oxidase deficiency can prevent anti-angiogenic activity in atherosclerotic vessel disease through a reduction in ROS production and increasing NO bioavailability.¹¹⁴

It has been shown that diabetes-induced overproduction of ROS also impairs post-ischaemic neovascularization.¹¹⁶ As such, the inhibition of oxidative stress during experimental diabetes restores important mediators necessary for angiogenesis, such as VEGF-A signalling and ischaemic vasculogenesis responses. In addition, hyperglycaemia-induced overproduction of ROS also impairs EPC function leading to the impairment of angiogenesis and vasculogenesis by augmenting p38MAPK phosphorylation in bone marrow mononuclear cells (BM-MNCs) and reducing BM-MNC differentiation into EPCs in diabetes.^117,118 Treatment of diabetic animals with N-acetyl cysteine over time improves EC function, which may help to normalize impaired angiogenesis in diabetes.¹¹⁹ There is other evidence that pre-treatment of the diabetic rat aorta with SOD and/or antioxidant probucol prevents the impairment of endothelium-dependent relaxation in aortic rings.¹²⁰ Likewise, pre-treatment with either SOD or catalase has been shown to improve endothelial dysfunction in streptozotocin-induced diabetic rats, suggesting that vascular production of both superoxide and hydrogen peroxide is pathologically important.¹²¹ This is consistent with the observation that vasodilation, a mediator of arteriogenesis, is attenuated through an ROS reduction in NO bioavailability during diabetes.¹²² Likewise, collateral vessel formation, capillary density, and blood flow recovery are impaired in SOD-deficient mice due to production of excessive superoxide, decreased NO bioactivity, and increased apoptosis.¹²³ These findings demonstrate that vascular growth and remodelling is tightly balanced by both ROS-producing oxidases and ROS-scavenging enzymes particularly in disease states.

Previous SectionNext Section

5. Signalling pathways leading to NO generation during ischaemic neovascularization

NO generation is now known to occur through multiple mechanisms including enzymatic and non-enzymatic pathways. Classical enzymatic mechanisms involve NO syntheses including eNOS, inducible nitric oxide synthase, and neuronal nitric oxide synthase that produce NO from L-arginine oxidation and reduction.¹²⁴ Other pathways such as the nitrite/NO system also generate NO via other non-classical pathways, through a reduction in nitrite anion back to NO.¹²⁴ Therefore, activation and subsequent interactions of various NO production pathways can be complex during chronic or intermittent tissue ischaemia.

5.1 Activation of the PKA/eNOS signalling pathway

Much effort has been made in defining the signalling pathways leading to the activation of eNOS. Regulation of eNOS activity is complex, involving various protein–protein interactions and numerous post-translational regulations such as serine/threonine phosphorylation at multiple sites.^125–127 Among them, the phosphorylation of serine residue at 1177 (Ser1177), which leads to maximal activation of eNOS activity, appears to be the most crucial and thus has been studied extensively. A number of kinases have been identified to phosphorylate eNOS, among them Akt-induced eNOS phosphorylation has been more clearly characterized.¹²⁷Akt phosphorylates eNOS at Ser1177 and is involved in the regulation of basal activation of eNOS and agonist-mediated stimulation.¹²⁸ Akt is predominantly found in the cytosol in inactive form and must translocate to the membrane as a prerequisite to both its own activation via phosphoinositide-3-kinase (PI3K) and the phosphorylation of eNOS.¹²⁹ In addition to Akt, AMP-activated protein kinase (AMPK), protein kinase C (PKC), and PKA have been also shown to phosphorylate eNOS.¹²⁷ Initially, a biochemical study found that PKA phosphorylated eNOS at least on Ser633 and Ser1177.¹³⁰ Subsequently, eNOS phosphorylation at both sites was induced by shear stress in a PKA-dependent but Akt-independent manner in bovine aortic ECs (BAEC).^131–133 Compared with Akt, PKA induces eNOS activation in a two-phased pattern, which mainly involves Ser1177 and Ser617. The onset of phosphorylation on Ser1177 is quick and calcium-dependent, while Ser633 phosphorylation is slow and calcium-independent, suggesting that Ser633 phosphorylation maintains sustained high activity of eNOS after initial activation by calcium influx and Ser1177 phosphorylation.¹²⁷ However, compared with the well-recognized role of Akt in eNOS activation, less attention has been paid to the role of PKA in eNOS/NO-mediated function.

5.2 PKA/eNOS signalling pathway in neovascularization

To date, a growing list of stimuli has been identified that influence eNOS activation and NO synthesis by the activation of PKA, and many of them are activators of neovascularization^134–140 including vasoactive substances such as bradykinin and prostacyclin, and growth factors such as VEGF.^27,141 Bradykinin is a potent agonist for endothelial NO production through the PKA-dependent phosphorylation of eNOS on Ser1177.¹³⁸ A previous study showed that the bradykinin B2 receptor mediates a pro-angiogenic signalling.¹³⁹ Prostacyclin, the major product of cyclooxygenase in the macrovascular endothelium, acts on its endothelial receptors to promote NO production via the activation of the cAMP/PKA signalling pathway.¹⁴⁰ It is known that prostacyclin and NO act synergistically in VEGF-mediated angiogenic signalling.¹³⁴ Prostaglandin E2, another product of the cyclooxygenase pathway, has also been implicated in modulating angiogenesis via the PKA/eNOS pathway.¹³⁵ The role of the PKA/eNOS pathway in neovascularization has been documented in numerous well-controlled studies with pharmacological compounds such as forskolin^28,142 and cilostazol, cAMP inducers.^137,143For example, Venkatesh et al.¹⁴⁴ reported that dipyridamole rapidly restores ischaemic limb blood flow and stimulates collateral artery perfusion via arteriogenesis activity through a PKA/eNOS/NO-dependent pathway. Similarly, Lu et al. have reported mechanisms of angiogenesis in Gab1-deficient mice revealing that the PKA/eNOS signalling pathway is critical in Gab1-mediated ischaemia and VEGF-induced angiogenesis bothin vivo and in vitro. These studies also showed that Gab1 deficiency caused defective endothelial tube formation that could be rescued by re-introduction of either constitutively active PKA or eNOS.¹⁴¹

Apart from above-mentioned evidence, ischaemia/hypoxia is known to induce EPC homing,⁶⁷ which is of vital importance in vascular repair and vasculogenesis. As a target gene of HIFs, VEGF, which is an activator of the PKA/eNOS pathway, is critical for SDF-1α-mediated EPC homing.¹⁴⁵ Thus, it is possible that PKA/eNOS signalling may enhance EPC recruitment to the sites of ischaemia to promote vasculogenesis. Consistent with this idea, cilostazol stimulates progenitor cell integrin expression, migration, and adhesion through cooperative activation of PKA and Epac signals.¹⁴⁶cAMP/PKA also enhances EPC differentiation via VEGFR2 and Neuropillin-1 induction as a blockade of PKA perturbs EPC differentiation and vascular formation in vitro and ex vivo, while over-expression of constitutive active PKA potently induces endothelial differentiation and vascular formation.¹⁴⁷

As discussed above, occlusion of a major artery increases mechanical stress through pre-existing collateral arterioles to facilitate vascular remodelling. Notably, mechanical forces are critical regulators of eNOS activity at both the transcriptional level and the post-translational level. Recent research suggests that laminar rather than oscillatory shear stress is the major activator of eNOS activity, and cyclic stretch seems to act as a secondary synergistic factor.^148,149 The mechanism of eNOS activation elicited by shear stress was first reported to be PKA but not Akt-dependent in BAEC. Further research confirms that shear stress induces a complex formed by Gab1/shp2/PKA/eNOS independent of Akt activation. Additionally, a two-phased eNOS activation pattern was observed when ECs were exposed to cyclic strain.¹⁵⁰ The first phase involves rapid phosphorylation of Ser1177 induced by calcium influx, and the second phase is sustained phosphorylation mainly through the PI3K–Akt signalling pathway. Thus far, it has been assumed that the activation of the eNOS/NO pathway mediates mechanical stress-induced angiogenesis through an activating PKA/eNOS pathway,^149,151 although a detailed intracellular signalling cascade needs to be further defined.

5.3 Cellular basis of PKA/eNOS-mediated neovascularization

Given the effects that the PKA/eNOS pathway exerts on all the processes of neovascularization, their mechanisms likely involve numerous targets at the cellular level. Studies revealed that the PKA/eNOS pathway regulates different processes through coordinated and synergistic modulation of multiple cell functions, such as endothelial proliferation, tube formation, and survival; induction of relaxation and cell arrest of vascular SMC;^152,153 and stimulation of homing and differentiation of EPCs. In ECs, PKA/eNOS signalling favours endothelial proliferation, tube formation, and survival partially through the crosstalk with the PI3K/Akt pathway, activating cell cycle regulators and phosphorylating the anti-apoptotic Bcl-2 family members.^154,155 In addition, the PKA/eNOS pathway induces endothelial migration via NO production and calcium influx by activating ion channels¹⁵⁶ and promotes endothelial wound healing through cytoskeletal reorganization of focal adhesions.¹³⁵Conversely, pre-treatment with PKA or eNOS inhibitors both significantly attenuates cilostazol-induced endothelial tube formation.¹³⁷ At the subcellular level, recent studies indicate that PKA and eNOS are co-localized in the endothelial lamellipodia located at cell contacts, indicating a possible role in regulating cell junction and vascular permeability.¹⁵⁷Indeed, PKA and Epac were demonstrated to stabilize EC junctions and enhance cell barrier function via integrin-dependent and -independent pathways.¹⁵⁸ Moreover, NO derived from pericytes plays an important anti-inflammatory role in mediating endothelial response to acute infection.^152,153 Endothelium-derived NO triggers the relaxation of vascular SMCs¹⁵⁹ and can inhibit SMC proliferation.⁸³ However, the importance of these responses for artery remodelling and arteriogenesis in ischaemic tissues is not well understood.¹⁶⁰ Additionally, NO also regulates EPC survival, migration, and homing. SDF-1α inhibits EPC apoptosis mainly through the Akt/eNOS pathway,¹⁶¹ and eNOS/NO nitrosylation of matrix metallopeptidase 9 (MMP-9) is critical for EPC mobilization and migration.¹⁶² However, future studies will be needed to explore the relationship and importance of PKA/eNOS signalling for these responses under ischaemic settings.

5.4 NO/nitrite/nitrate system

The NO metabolites nitrite (NO₂⁻) and nitrate (NO₃⁻) anions were traditionally thought to be inert end products of endogenous NO oxidation. However, recent studies show that these anions can be recycledin vivo to form NO and other bioactive nitrogen oxides representing an important alternative source of NO to the classical L-arginine/NO synthase pathway particularly in hypoxic states.¹⁶³ Bioactivation of nitrate to nitrite from dietary or endogenous sources requires its entry into the enterosalivary system whereby nitrate is reduced to nitrite by oral commensal bacteria. However, nitrite is unique in its redox position between oxidative and reductive chemistry and its relative stability in blood and tissues.^164,165 Nitrite can be reduced to NO by numerous pathways such as deoxyhaemoglobin, deoxymyoglobin, xanthine oxidoreductase, ascorbate, polyphenols, and protons.¹⁶³ A reduction in nitrite to NO is increased under ischaemic conditions particularly when oxygen-dependent NOS activities are compromised. Thus, bioavailable NO equivalents can be stored in blood and tissue in the form of nitrite, which can act in an endocrine fashion within the blood, accumulate in various tissues, and undergo reduction back to NO under certain pathophysiological states.^124,166 Together, the nitrite/NO system works in cooperation to maintain NO bioavailability in NOS-dependent and -independent ways in conjunction with blood and tissue factors.

We have shown that the nitrite/NO system can be activated in a PKA-dependent manner to stimulate arteriogenesis and angiogenesis, thus restoring blood flow in ischaemic tissue.¹⁴⁴ Similarly, other studies have shown that adenosine-dependent eNOS activation via adenylate cyclase and PKA activation leads to tissue production of NO implicating initiation of nitrite/NO endocrine responses and their interaction with other pathways.^167,168 This is further supported by Elrod et al.¹⁶⁹ that reported cardiac-specific eNOS transgenic-derived NO transported via plasma nitrite acts in distant organs to attenuate cellular injury during ischaemia. Finally, reports also reveal that nitrite reduction to NO and NO-modified proteins during pathological and physiological hypoxia contributes to physiological hypoxic signalling, vasodilation, modulation of cellular respiration, and the cellular response to ischaemic stress.^163,170 Thus, the NO/nitrite system is an important endocrine pathway to maintain NO particularly in hypoxic conditions that is regulated by PKA.

5.5 Signalling interactions between PKA/eNOS and other angiogenic pathways

As a recently defined angiogenic regulator, the PKA/eNOS pathway interacts with many conventional angiogenic-signalling pathways. Among these, some serve as substrates of PKA, others act in parallel with PKA, while converging synergistically at eNOS activation. Epac is the other major ubiquitously expressed target of cAMP aside from PKA, and it often acts synergistically with PKA in regulating endothelial behaviours such as tube formation, migration, and barrier function. Forskolin, a cAMP inducer, stimulates in vitro HUVEC tube formation and in vivoangiogenesis through a coordinated crosstalk between PKA-dependent CRE-mediated VEGF expression and Epac-dependent Erk activation and PI3K/Akt/eNOS signalling.¹⁴² The activation of Epac1 and PKA by cAMP results in the stimulation of two parallel signalling pathways compensating each other, enhancing endothelial integrity and barrier function by modulating circumferential actin, while promoting HUVEC integrin-mediated migration.¹⁷¹ The PI3K/Akt pathway acts synergistically with the PKA/eNOS pathway to modulate endothelial angiogenesis. Boo et al. suggested that coordinated interaction between Akt and PKA is an important mechanism in regulating eNOS activity in response to mechanical shear stress.¹³¹ Besides, cilostazol enhances tube formation in human aortic ECs by inducing NO production via a cAMP/PKA- and PI3K/Akt -dependent eNOS activating mechanism.¹³⁷Finally, cAMP/PKA signalling can activate p85α subunit of PI3K and trigger Akt activation, inhibiting endothelial apoptosis, while maintaining proliferation, thus exerting a protective effect against vascular injury.¹⁷²

Apart from those mentioned above, the PKA/eNOS pathway also interacts with AMPK/eNOS and PLC/PKC/eNOS pathways. While PLC/PKC activation inhibits eNOS activation via Thr495 phosphorylation and Ser1177 de-phosphorylation on eNOS,¹⁷³ AMPK activation enhances eNOS activity.^174,175 cAMP-elevating agents significantly attenuate AMPK Thr172 phosphorylation and enhance Ser485/491 phosphorylation through PKA activation in several different cell lines, attenuating its activity.¹⁷⁴ Thrombin and histamine induce AMPK phosphorylation on Thr172 and eNOS phosphorylation on Ser1177, and the latter is strongly inhibited by pre-treatment of H-89, an inhibitor for PKA and AMPK, although was unaffected by the cAMP competitive analogue cAMPs, indicating the involvement of both signalling pathways.¹⁷⁵ Furthermore, in an in vivo rat hind limb ischaemia model, a calcitonin gene-related peptide promotes blood flow recovery and angiogenesis through activating eNOS phosphorylation on Ser1177 via AMPK in HUVEC, which was blocked by a cAMP/PKA inhibitor.¹³⁶

In summary, all the evidence suggests that under pathophysiological conditions, various stimuli are able to promote neovascularization involving the PKA/eNOS signalling pathway. PKA signalling interacts with other pathways such as Akt and AMPK, converges on the activation of eNOS, and leads to vessel vascular growth (Figure 2). Given the complex nature of PKA signalling, it remains a salient challenge to determine the coordination of multiple signalling interactions that may finely modulate neovascularization. In addition, these interactions were largely examined with in vitro cultured cell system and in vivo ischaemic neovascularization is complex with multiple factors (mechanical, chemical, metabolic, and immunological), influencing the process of tissue injury and repair. Thus, it is perhaps not surprising that even more complicated interactions of signalling pathways are involved in ischaemic neovascularization.

View larger version:

In this page
In a new window

Download as PowerPoint Slide

Figure 2

PKA-dependent signalling pathway is activated by various stimuli (e.g. mechanical forces and chemical ligands) regulating vessel growth. PKA signalling interacts with other intracellular pathways such as Akt and AMPK, converging onto the activation of eNOS that exerts multiple cellular functions synergistically leading to vessel growth. It should be pointed out that the actions of eNOS/NO on the phenotypes of ECs and SMCs may be context-specific dependent on several physiological and pathological conditions.

Previous SectionNext Section

6. Different therapies that potentiate the PKA/eNOS and nitrite/NO system

There are some drugs that have shown their effects involving PKA/eNOS and nitrite/NO signalling pathways. Among them, we discuss two that have clearly been reported to influence these pathways including statins and dipyridamole.

6.1 Statins

Statins are established anti-hypercholesterolaemia drugs that can stimulate ischaemic angiogenesis through an Akt/eNOS/NO-dependent pathway.¹⁷⁶ Brouet et al.¹⁷⁷ also found that statins stimulate hsp90 and Akt/eNOS pathway which helps prevent eNOS uncoupling, thus maintaining eNOS activity and NO bioavailability. Harris et al. further showed that the treatment of BAEC with statins stimulated eNOS phosphorylation at Ser1179 and Ser617, which was blocked by the PI3 kinase inhibitor wortmannin, and phosphorylation at Ser635 was blocked by the PKA inhibitor KT-5720. Thus, demonstrating that eNOS is acutely activated by statins through both PKA and Akt.¹⁷⁸ Similarly, statins improve EPC mobilization and myocardial neovascularization after infarction by increasing endothelial NO bioavailability. Statins enhance endothelial NO bioavailability by both promoting endothelial production and preventing NO inactivation by free radicals.^176,179,180 Finally, it has also been reported that statin therapy stimulates neovascularization at the myocardial infarct border zone of mice and this effect is absent in eNOS-KO mice.¹⁸¹ In summary, statins induce ischaemic neovascularization via both PKA/eNOS and Akt/eNOS pathways but have not been useful in stimulating clinical therapeutic angiogenesis.

6.2 Dipyridamole

As briefly mentioned earlier, we have recently examined the effect of dipyridamole on therapeutic angiogenesis.¹⁸² Dipyridamole augmented angiogenesis owing to PKA-dependent eNOS activation which enhanced the production of NO and subsequent plasma nitrite. Dipyridamole therapy not only increased eNOS activity but also increased NO bioavailability in tissues, leading to an increase in plasma nitrite anion in non-ischaemic tissue supporting the hypothesis of an endocrine nitrite/NO pathway that was regulated in a PKA-dependent manner.¹⁶⁹Dipyridamole can also augment downstream signalling pathways of NO by increasing intracellular levels of cGMP, thereby potentiating NO/cGMP-mediated vasodilation and enhancing ischaemia-induced angiogenesis.¹⁸³ Thus, dipyridamole stimulates ischaemic neovascularization via an activating PKA–eNOS–NO–cGMP pathway.

While both pharmaceutical agents highlight the potential importance of PKA/eNOS signalling for vascular remodelling therapy, novel approaches targeting these pathways may also be useful.

Previous SectionNext Section

7. Perspectives and conclusions

The concept of therapeutic angiogenesis remains an attractive medical approach for the treatment of ischaemic diseases. However, a better understanding of the complex molecular mechanisms and intracellular signalling network underlying ischaemic neovascularization is necessary to provide more effective strategies. Therefore, it is important to clarify interactions among the NO-related signalling pathways that can increase NO bioavailability in ischaemic neovascularization. It is well known that the bioavailability of NO is increased by eNOS phosphorylation either by Akt or PKA and that NO exerts its effect via sGC/cGMP kinase pathways. However, NO is an unstable gasotransmitter with a short half-life influenced by the presence of oxygen-derived free radicals. Moreover, it is difficult to selectively administer NO discretely to tissues in vivo. Thus, additional study is needed to develop novel pharmaceutical approaches to increase NO bioavailability involving PKA-dependent signalling. Additional molecular studies are necessary to determine the exact role of PKA in vascular remodelling response using sophisticated genetic models and specific pharmacological interventions. Due to the signalling complexity of PKA with many substrates and interacting proteins,^184,185 a combination of approaches involving proteomics and system biology may be useful in elucidating roles of PKA/eNOS in ischaemic neovascularization.

Conflict of interest: C.G.K. has intellectual property on the use of nitrite for ischaemic vascular remodelling and a financial interest in TheraVasc Inc.

Previous SectionNext Section

Funding

C.G.K. is the recipient of an ADA Basic Science Grant 1-10-BS-84 and NIH Grant HL80482 and S.C.B is funded by a fellowship from the Malcolm Feist Cardiovascular Research Endowment, LSU Health Sciences Center, Shreveport. J.L. is supported by research grants from the National Science Funds of China (nos 81070115 and 81170098) and the Major State Basic Research Development Program of China (no. 2012CB945100).

Previous SectionNext Section

Footnotes

↵† These authors contributed equally to this work.

Previous Section

References

↵
1. Ferrara N
. Molecular and biological properties of vascular endothelial growth factor. J Mol Med (Berl) 1999;77:527-543.
CrossRefMedlineWeb of Science
1. Folkman J
. Tumor angiogenesis: therapeutic implications. N Engl J Med1971;285:1182-1186.
MedlineWeb of Science
↵
1. Shing Y,
2. Folkman J,
3. Sullivan R,
4. Butterfield C,
5. Murray J,
6. Klagsbrun M
. Heparin affinity: purification of a tumor-derived capillary endothelial cell growth factor.Science 1984;223:1296-1299.
Abstract/FREE Full Text
↵
1. Takeshita S,
2. Zheng LP,
3. Brogi E,
4. Kearney M,
5. Pu LQ,
6. Bunting S,
7. et al
. Therapeutic angiogenesis. A single intraarterial bolus of vascular endothelial growth factor augments revascularization in a rabbit ischemic hind limb model. J Clin Invest1994;93:662-670.
MedlineWeb of Science
↵
1. Henry TD,
2. Annex BH,
3. McKendall GR,
4. Azrin MA,
5. Lopez JJ,
6. Giordano FJ,
7. et al
. The VIVA trial: vascular endothelial growth factor in ischemia for vascular angiogenesis.Circulation 2003;107:1359-1365.
Abstract/FREE Full Text
1. Freedman SB,
2. Isner JM
. Therapeutic angiogenesis for ischemic cardiovascular disease. J Mol Cell Cardiol 2001;33:379-393.
CrossRefMedlineWeb of Science
1. Simons M,
2. Annex BH,
3. Laham RJ,
4. Kleiman N,
5. Henry T,
6. Dauerman H,
7. et al
.Pharmacological treatment of coronary artery disease with recombinant fibroblast growth factor-2: double-blind, randomized, controlled clinical trial. Circulation2002;105:788-793.
Abstract/FREE Full Text
↵
1. Lekas M,
2. Lekas P,
3. Latter DA,
4. Kutryk MB,
5. Stewart DJ
. Growth factor-induced therapeutic neovascularization for ischaemic vascular disease: time for a re-evaluation? Curr Opin Cardiol 2006;21:376-384.
MedlineWeb of Science
↵
1. Tongers J,
2. Roncalli JG,
3. Losordo DW
. Therapeutic angiogenesis for critical limb ischemia: microvascular therapies coming of age. Circulation 2008;118:9-16.
FREE Full Text
↵
1. Cao Y
. Therapeutic angiogenesis for ischemic disorders: what is missing for clinical benefits? Discov Med 2010;9:179-184.
Medline
↵
1. Carmeliet P
. Angiogenesis in health and disease. Nat Med 2003;9:653-660.
CrossRefMedlineWeb of Science
↵
1. Semenza GL
. Vasculogenesis, angiogenesis, and arteriogenesis: mechanisms of blood vessel formation and remodeling. J Cell Biochem 2007;102:840-847.
CrossRefMedlineWeb of Science
↵
1. Vincent KA,
2. Jiang C,
3. Boltje I,
4. Kelly RA
. Gene therapy progress and prospects: therapeutic angiogenesis for ischemic cardiovascular disease. Gene Ther2007;14:781-789.
CrossRefMedlineWeb of Science
↵
1. Chen Z,
2. Rubin J,
3. Tzima E
. Role of PECAM-1 in arteriogenesis and specification of preexisting collaterals. Circ Res 2010;107:1355-1363.
Abstract/FREE Full Text
↵
1. Demicheva E,
2. Hecker M,
3. Korff T
. Stretch-induced activation of the transcription factor activator protein-1 controls monocyte chemoattractant protein-1 expression during arteriogenesis. Circ Res 2008;103:477-484.
Abstract/FREE Full Text
↵
1. Asahara T,
2. Murohara T,
3. Sullivan A,
4. Silver M,
5. van der Zee R,
6. Li T,
7. et al
. Isolation of putative progenitor endothelial cells for angiogenesis. Science1997;275:964-967.
Abstract/FREE Full Text
↵
1. Kastrup J
. Gene therapy and angiogenesis in patients with coronary artery disease. Expert Rev Cardiovasc Ther 2010;8:1127-1138.
CrossRefMedline
↵
1. Patel TH,
2. Kimura H,
3. Weiss CR,
4. Semenza GL,
5. Hofmann LV
. Constitutively active HIF-1alpha improves perfusion and arterial remodeling in an endovascular model of limb ischemia. Cardiovasc Res 2005;68:144-154.
Abstract/FREE Full Text
↵
1. Fukumura D,
2. Xu L,
3. Chen Y,
4. Gohongi T,
5. Seed B,
6. Jain RK
. Hypoxia and acidosis independently up-regulate vascular endothelial growth factor transcription in brain tumors in vivo. Cancer Res 2001;61:6020-6024.
Abstract/FREE Full Text
↵
1. Ito WD,
2. Arras M,
3. Winkler B,
4. Scholz D,
5. Schaper J,
6. Schaper W
. Monocyte chemotactic protein-1 increases collateral and peripheral conductance after femoral artery occlusion. Circ Res 1997;80:829-837.
Abstract/FREE Full Text
↵
1. Ceradini DJ,
2. Gurtner GC
. Homing to hypoxia: HIF-1 as a mediator of progenitor cell recruitment to injured tissue. Trends Cardiovasc Med 2005;15:57-63.
CrossRefMedlineWeb of Science
↵
1. Couffinhal T,
2. Silver M,
3. Zheng LP,
4. Kearney M,
5. Witzenbichler B,
6. Isner JM
. Mouse model of angiogenesis. Am J Pathol 1998;152:1667-1679.
MedlineWeb of Science
1. Fukumura D,
2. Gohongi T,
3. Kadambi A,
4. Izumi Y,
5. Ang J,
6. Yun CO,
7. et al
. Predominant role of endothelial nitric oxide synthase in vascular endothelial growth factor-induced angiogenesis and vascular permeability. Proc Natl Acad Sci USA2001;98:2604-2609.
Abstract/FREE Full Text
↵
1. Murohara T,
2. Asahara T,
3. Silver M,
4. Bauters C,
5. Masuda H,
6. Kalka C,
7. et al
. Nitric oxide synthase modulates angiogenesis in response to tissue ischemia. J Clin Invest1998;101:2567-2578.
MedlineWeb of Science
↵
1. Yu J,
2. deMuinck ED,
3. Zhuang Z,
4. Drinane M,
5. Kauser K,
6. Rubanyi GM,
7. et al
.Endothelial nitric oxide synthase is critical for ischemic remodeling, mural cell recruitment, and blood flow reserve. Proc Natl Acad Sci USA2005;102:10999-11004.
Abstract/FREE Full Text
↵
1. Kim S,
2. Bakre M,
3. Yin H,
4. Varner JA
. Inhibition of endothelial cell survival and angiogenesis by protein kinase A. J Clin Invest 2002;110:933-941.
CrossRefMedlineWeb of Science
↵
1. Thaker PH,
2. Han LY,
3. Kamat AA,
4. Arevalo JM,
5. Takahashi R,
6. Lu C,
7. et al
. Chronic stress promotes tumor growth and angiogenesis in a mouse model of ovarian carcinoma. Nat Med 2006;12:939-944.
CrossRefMedlineWeb of Science
↵
1. Amano H,
2. Ando K,
3. Minamida S,
4. Hayashi I,
5. Ogino M,
6. Yamashina S,
7. et al
.Adenylate cyclase/protein kinase A signaling pathway enhances angiogenesis through induction of vascular endothelial growth factor in vivo. Jpn J Pharmacol2001;87:181-188.
CrossRefMedline
↵
1. Bodnar RJ,
2. Yates CC,
3. Wells A
. IP-10 blocks vascular endothelial growth factor-induced endothelial cell motility and tube formation via inhibition of calpain. Circ Res 2006;98:617-625.
Abstract/FREE Full Text
↵
1. Carmeliet P
. Mechanisms of angiogenesis and arteriogenesis. Nat Med2000;6:389-395.
CrossRefMedlineWeb of Science
1. Wahlberg E
. Angiogenesis and arteriogenesis in limb ischemia. J Vasc Surg2003;38:198-203.
CrossRefMedlineWeb of Science
↵
1. Carmeliet P,
2. Jain RK
. Angiogenesis in cancer and other diseases. Nature2000;407:249-257.
CrossRefMedline
↵
1. Rivilis I,
2. Milkiewicz M,
3. Boyd P,
4. Goldstein J,
5. Brown MD,
6. Egginton S,
7. et al
.Differential involvement of MMP-2 and VEGF during muscle stretch- versus shear stress-induced angiogenesis. Am J Physiol Heart Circ Physiol2002;283:H1430-H1438.
Abstract/FREE Full Text
↵
1. Brownlee M
. Biochemistry and molecular cell biology of diabetic complications.Nature 2001;414:813-820.
CrossRefMedline
↵
1. Perez-Zoghbi JF,
2. Bai Y,
3. Sanderson MJ
. Nitric oxide induces airway smooth muscle cell relaxation by decreasing the frequency of agonist-induced Ca²⁺oscillations. J Gen Physiol 2010;135:247-259.
Abstract/FREE Full Text
↵
1. Gallo O,
2. Masini E,
3. Morbidelli L,
4. Franchi A,
5. Fini-Storchi I,
6. Vergari WA,
7. et al
. Role of nitric oxide in angiogenesis and tumor progression in head and neck cancer. J Natl Cancer Inst 1998;90:587-596.
Abstract/FREE Full Text
↵
1. Bogdan C
. Nitric oxide and the regulation of gene expression. Trends Cell Biol2001;11:66-75.
CrossRefMedlineWeb of Science
↵
1. Papapetropoulos A,
2. Desai KM,
3. Rudic RD,
4. Mayer B,
5. Zhang R,
6. Ruiz-Torres MP,
7. et al
. Nitric oxide synthase inhibitors attenuate transforming-growth-factor-beta 1-stimulated capillary organization in vitro. Am J Pathol 1997;150:1835-1844.
MedlineWeb of Science
↵
1. Hood JD,
2. Meininger CJ,
3. Ziche M,
4. Granger HJ
. VEGF upregulates eNOS message, protein, and NO production in human endothelial cells. Am J Physiol1998;274:H1054-H1058.
MedlineWeb of Science
↵
1. van der Zee R,
2. Murohara T,
3. Luo Z,
4. Zollmann F,
5. Passeri J,
6. Lekutat C,
7. et al
.Vascular endothelial growth factor/vascular permeability factor augments nitric oxide release from quiescent rabbit and human vascular endothelium. Circulation1997;95:1030-1037.
Abstract/FREE Full Text
↵
1. Ziche M,
2. Morbidelli L,
3. Masini E,
4. Amerini S,
5. Granger HJ,
6. Maggi CA,
7. et al
. Nitric oxide mediates angiogenesis in vivo and endothelial cell growth and migration in vitro promoted by substance P. J Clin Invest 1994;94:2036-2044.
MedlineWeb of Science
↵
1. Ziche M,
2. Morbidelli L,
3. Masini E,
4. Granger H,
5. Geppetti P,
6. Ledda F
. Nitric oxide promotes DNA synthesis and cyclic GMP formation in endothelial cells from postcapillary venules. Biochem Biophys Res Commun 1993;192:1198-1203.
CrossRefMedlineWeb of Science
↵
1. Ziche M,
2. Morbidelli L,
3. Choudhuri R,
4. Zhang HT,
5. Donnini S,
6. Granger HJ,
7. et al
.Nitric oxide synthase lies downstream from vascular endothelial growth factor-induced but not basic fibroblast growth factor-induced angiogenesis. J Clin Invest1997;99:2625-2634.
MedlineWeb of Science
↵
1. Babaei S,
2. Teichert-Kuliszewska K,
3. Monge JC,
4. Mohamed F,
5. Bendeck MP,
6. StewartDJ
. Role of nitric oxide in the angiogenic response in vitro to basic fibroblast growth factor. Circ Res 1998;82:1007-1015.
Abstract/FREE Full Text
↵
1. Chen CH,
2. Cartwright J Jr.,
3. Li Z,
4. Lou S,
5. Nguyen HH,
6. Gotto AM Jr.,
7. et al
.Inhibitory effects of hypercholesterolemia and ox-LDL on angiogenesis-like endothelial growth in rabbit aortic explants. Essential role of basic fibroblast growth factor. Arterioscler Thromb Vasc Biol 1997;17:1303-1312.
Abstract/FREE Full Text
↵
1. Van Belle E,
2. Rivard A,
3. Chen D,
4. Silver M,
5. Bunting S,
6. Ferrara N,
7. et al
.Hypercholesterolemia attenuates angiogenesis but does not preclude augmentation by angiogenic cytokines. Circulation 1997;96:2667-2674.
Abstract/FREE Full Text
↵
1. Murohara T,
2. Witzenbichler B,
3. Spyridopoulos I,
4. Asahara T,
5. Ding B,
6. Sullivan A,
7. et al
. Role of endothelial nitric oxide synthase in endothelial cell migration. Arterioscler Thromb Vasc Biol 1999;19:1156-1161.
Abstract/FREE Full Text
↵
1. Morbidelli L,
2. Chang CH,
3. Douglas JG,
4. Granger HJ,
5. Ledda F,
6. Ziche M
. Nitric oxide mediates mitogenic effect of VEGF on coronary venular endothelium. Am J Physiol1996;270:H411-H415.
MedlineWeb of Science
↵
1. Verma S,
2. Wang CH,
3. Li SH,
4. Dumont AS,
5. Fedak PW,
6. Badiwala MV,
7. et al
. A self-fulfilling prophecy: C-reactive protein attenuates nitric oxide production and inhibits angiogenesis. Circulation 2002;106:913-919.
Abstract/FREE Full Text
↵
1. Ziche M,
2. Morbidelli L
. Nitric oxide and angiogenesis. J Neurooncol2000;50:139-148.
CrossRefMedline
↵
1. Ziche M,
2. Morbidelli L,
3. Parenti A,
4. Amerini S,
5. Granger HJ,
6. Maggi CA
. Substance P increases cyclic GMP levels on coronary postcapillary venular endothelial cells. Life Sci 1993;53:PL229-PL234.
CrossRefMedlineWeb of Science
↵
1. Dulak J,
2. Jozkowicz A,
3. Dembinska-Kiec A,
4. Guevara I,
5. Zdzienicka A,
6. Zmudzinska-Grochot D,
7. et al
. Nitric oxide induces the synthesis of vascular endothelial growth factor by rat vascular smooth muscle cells. Arterioscler Thromb Vasc Biol 2000;20:659-666.
Abstract/FREE Full Text
↵
1. Ziche M,
2. Parenti A,
3. Ledda F,
4. Dell'Era P,
5. Granger HJ,
6. Maggi CA,
7. et al
. Nitric oxide promotes proliferation and plasminogen activator production by coronary venular endothelium through endogenous bFGF. Circ Res 1997;80:845-852.
Abstract/FREE Full Text
↵
1. Hood J,
2. Granger HJ
. Protein kinase G mediates vascular endothelial growth factor-induced Raf-1 activation and proliferation in human endothelial cells. J Biol Chem 1998;273:23504-23508.
Abstract/FREE Full Text
↵
1. Parenti A,
2. Morbidelli L,
3. Cui XL,
4. Douglas JG,
5. Hood JD,
6. Granger HJ,
7. et al
. Nitric oxide is an upstream signal of vascular endothelial growth factor-induced extracellular signal-regulated kinase1/2 activation in postcapillary endothelium. J Biol Chem 1998;273:4220-4226.
Abstract/FREE Full Text
↵
1. Noiri E,
2. Lee E,
3. Testa J,
4. Quigley J,
5. Colflesh D,
6. Keese CR,
7. et al
. Podokinesis in endothelial cell migration: role of nitric oxide. Am J Physiol 1998;274:C236-C244.
MedlineWeb of Science
↵
1. Kuzuya M,
2. Iguchi A
. Role of matrix metalloproteinases in vascular remodeling. J Atheroscler Thromb 2003;10:275-282.
Medline
↵
1. Lopez-Rivera E,
2. Lizarbe TR,
3. Martinez-Moreno M,
4. Lopez-Novoa JM,
5. Rodriguez-Barbero A,
6. Rodrigo J,
7. et al
. Matrix metalloproteinase 13 mediates nitric oxide activation of endothelial cell migration. Proc Natl Acad Sci USA2005;102:3685-3690.
Abstract/FREE Full Text
↵
1. Genis L,
2. Gonzalo P,
3. Tutor AS,
4. Galvez BG,
5. Martinez-Ruiz A,
6. Zaragoza C,
7. et al
.Functional interplay between endothelial nitric oxide synthase and membrane type 1 matrix metalloproteinase in migrating endothelial cells. Blood2007;110:2916-2923.
Abstract/FREE Full Text
↵
1. Gurjar MV,
2. Sharma RV,
3. Bhalla RC
. eNOS gene transfer inhibits smooth muscle cell migration and MMP-2 and MMP-9 activity. Arterioscler Thromb Vasc Biol1999;19:2871-2877.
Abstract/FREE Full Text
↵
1. Okamoto T,
2. Akaike T,
3. Nagano T,
4. Miyajima S,
5. Suga M,
6. Ando M,
7. et al
. Activation of human neutrophil procollagenase by nitrogen dioxide and peroxynitrite: a novel mechanism for procollagenase activation involving nitric oxide. Arch Biochem Biophys 1997;342:261-274.
CrossRefMedlineWeb of Science
1. Rajagopalan S,
2. Meng XP,
3. Ramasamy S,
4. Harrison DG,
5. Galis ZS
. Reactive oxygen species produced by macrophage-derived foam cells regulate the activity of vascular matrix metalloproteinases in vitro. Implications for atherosclerotic plaque stability. J Clin Invest 1996;98:2572-2579.
MedlineWeb of Science
1. Wang W,
2. Sawicki G,
3. Schulz R
. Peroxynitrite-induced myocardial injury is mediated through matrix metalloproteinase-2. Cardiovasc Res 2002;53:165-174.
Abstract/FREE Full Text
↵
1. Wu J,
2. Akaike T,
3. Hayashida K,
4. Okamoto T,
5. Okuyama A,
6. Maeda H
. Enhanced vascular permeability in solid tumor involving peroxynitrite and matrix metalloproteinases. Jpn J Cancer Res 2001;92:439-451.
CrossRefWeb of Science
↵
1. Yamaguchi J,
2. Kusano KF,
3. Masuo O,
4. Kawamoto A,
5. Silver M,
6. Murasawa S,
7. et al
.Stromal cell-derived factor-1 effects on ex vivo expanded endothelial progenitor cell recruitment for ischemic neovascularization. Circulation 2003;107:1322-1328.
Abstract/FREE Full Text
↵
1. Kawamoto A,
2. Gwon HC,
3. Iwaguro H,
4. Yamaguchi JI,
5. Uchida S,
6. Masuda H,
7. et al
.Therapeutic potential of ex vivo expanded endothelial progenitor cells for myocardial ischemia. Circulation 2001;103:634-637.
Abstract/FREE Full Text
↵
1. Takahashi T,
2. Kalka C,
3. Masuda H,
4. Chen D,
5. Silver M,
6. Kearney M,
7. et al
. Ischemia- and cytokine-induced mobilization of bone marrow-derived endothelial progenitor cells for neovascularization. Nat Med 1999;5:434-438.
CrossRefMedlineWeb of Science
↵
1. Gill M,
2. Dias S,
3. Hattori K,
4. Rivera ML,
5. Hicklin D,
6. Witte L,
7. et al
. Vascular trauma induces rapid but transient mobilization of VEGFR2(+)AC133(+) endothelial precursor cells. Circ Res 2001;88:167-174.
Abstract/FREE Full Text
↵
1. Laufs U,
2. Werner N,
3. Link A,
4. Endres M,
5. Wassmann S,
6. Jurgens K,
7. et al
. Physical training increases endothelial progenitor cells, inhibits neointima formation, and enhances angiogenesis. Circulation 2004;109:220-226.
Abstract/FREE Full Text
↵
1. Fukai T,
2. Siegfried MR,
3. Ushio-Fukai M,
4. Cheng Y,
5. Kojda G,
6. Harrison DG
.Regulation of the vascular extracellular superoxide dismutase by nitric oxide and exercise training. J Clin Invest 2000;105:1631-1639.
MedlineWeb of Science
↵
1. Vasa M,
2. Fichtlscherer S,
3. Adler K,
4. Aicher A,
5. Martin H,
6. Zeiher AM,
7. et al
. Increase in circulating endothelial progenitor cells by statin therapy in patients with stable coronary artery disease. Circulation 2001;103:2885-2890.
Abstract/FREE Full Text
↵
1. Heil M,
2. Eitenmuller I,
3. Schmitz-Rixen T,
4. Schaper W
. Arteriogenesis versus angiogenesis: similarities and differences. J Cell Mol Med 2006;10:45-55.
CrossRefMedlineWeb of Science
↵
1. Ito WD,
2. Arras M,
3. Scholz D,
4. Winkler B,
5. Htun P,
6. Schaper W
. Angiogenesis but not collateral growth is associated with ischemia after femoral artery occlusion. Am J Physiol 1997;273:H1255-H1265.
MedlineWeb of Science
↵
1. Heil M,
2. Schaper W
. Influence of mechanical, cellular, and molecular factors on collateral artery growth (arteriogenesis). Circ Res 2004;95:449-458.
Abstract/FREE Full Text
↵
1. van Royen N,
2. Piek JJ,
3. Schaper W,
4. Fulton WF
. A critical review of clinical arteriogenesis research. J Am Coll Cardiol 2009;55:17-25.
CrossRefMedlineWeb of Science
↵
1. Rudic RD,
2. Sessa WC
. Nitric oxide in endothelial dysfunction and vascular remodeling: clinical correlates and experimental links. Am J Hum Genet1999;64:673-677.
CrossRefMedlineWeb of Science
↵
1. Sessa WC,
2. Pritchard K,
3. Seyedi N,
4. Wang J,
5. Hintze TH
. Chronic exercise in dogs increases coronary vascular nitric oxide production and endothelial cell nitric oxide synthase gene expression. Circ Res 1994;74:349-353.
Abstract/FREE Full Text
↵
1. Lee EW,
2. Michalkiewicz M,
3. Kitlinska J,
4. Kalezic I,
5. Switalska H,
6. Yoo P,
7. et al
.Neuropeptide Y induces ischemic angiogenesis and restores function of ischemic skeletal muscles. J Clin Invest 2003;111:1853-1862.
CrossRefMedlineWeb of Science
↵
1. Robich MP,
2. Matyal R,
3. Chu LM,
4. Feng J,
5. Xu SH,
6. Laham RJ,
7. et al
. Effects of neuropeptide Y on collateral development in a swine model of chronic myocardial ischemia. J Mol Cell Cardiol 2010;49:1022-1030.
CrossRefMedline
↵
1. Ozaki M,
2. Kawashima S,
3. Hirase T,
4. Yamashita T,
5. Namiki M,
6. Inoue N,
7. et al
.Overexpression of endothelial nitric oxide synthase in endothelial cells is protective against ischemia–reperfusion injury in mouse skeletal muscle. Am J Pathol2002;160:1335-1344.
MedlineWeb of Science
↵
1. Dai S,
2. He Y,
3. Zhang H,
4. Yu L,
5. Wan T,
6. Xu Z,
7. et al
. Endothelial-specific expression of mitochondrial thioredoxin promotes ischemia-mediated arteriogenesis and angiogenesis. Arterioscler Thromb Vasc Biol 2009;29:495-502.
Abstract/FREE Full Text
↵
1. Desai A,
2. Miller MJ,
3. Huang X,
4. Warren JS
. Nitric oxide modulates MCP-1 expression in endothelial cells: implications for the pathogenesis of pulmonary granulomatous vasculitis. Inflammation 2003;27:213-223.
CrossRefMedlineWeb of Science
↵
1. Tsihlis ND,
2. Oustwani CS,
3. Vavra AK,
4. Jiang Q,
5. Keefer LK,
6. Kibbe MR
. Nitric oxide inhibits vascular smooth muscle cell proliferation and neointimal hyperplasia by increasing the ubiquitination and degradation of UbcH10. Cell Biochem Biophys2011;60:89-97.
CrossRefMedline
↵
1. Forstermann U
. Oxidative stress in vascular disease: causes, defense mechanisms and potential therapies. Nat Clin Pract Cardiovasc Med2008;5:338-349.
CrossRefMedlineWeb of Science
↵
1. Hilenski LL,
2. Clempus RE,
3. Quinn MT,
4. Lambeth JD,
5. Griendling KK
. Distinct subcellular localizations of Nox1 and Nox4 in vascular smooth muscle cells.Arterioscler Thromb Vasc Biol 2004;24:677-683.
Abstract/FREE Full Text
↵
1. Zhang DX,
2. Gutterman DD
. Mitochondrial reactive oxygen species-mediated signaling in endothelial cells. Am J Physiol Heart Circ Physiol2007;292:H2023-2031.
Abstract/FREE Full Text
↵
1. del Rio LA,
2. Sandalio LM,
3. Corpas FJ,
4. Palma JM,
5. Barroso JB
. Reactive oxygen species and reactive nitrogen species in peroxisomes. Production, scavenging, and role in cell signaling. Plant Physiol 2006;141:330-335.
FREE Full Text
1. Jackson MJ,
2. Pye D,
3. Palomero J
. The production of reactive oxygen and nitrogen species by skeletal muscle. J Appl Physiol 2007;102:1664-1670.
Abstract/FREE Full Text
↵
1. Paravicini TM,
2. Touyz RM
. NADPH oxidases, reactive oxygen species, and hypertension: clinical implications and therapeutic possibilities. Diabetes Care2008;31(Suppl. 2):S170-S180.
Abstract/FREE Full Text
↵
1. Forman HJ,
2. Maiorino M,
3. Ursini F
. Signaling functions of reactive oxygen species.Biochemistry 2010;49:835-842.
CrossRefMedlineWeb of Science
↵
1. Halliwell B
. Oxygen and nitrogen are pro-carcinogens. Damage to DNA by reactive oxygen, chlorine and nitrogen species: measurement, mechanism and the effects of nutrition. Mutat Res 1999;443:37-52.
MedlineWeb of Science
↵
1. Deshpande NN,
2. Sorescu D,
3. Seshiah P,
4. Ushio-Fukai M,
5. Akers M,
6. Yin Q,
7. et al
.Mechanism of hydrogen peroxide-induced cell cycle arrest in vascular smooth muscle. Antioxid Redox Signal 2002;4:845-854.
CrossRefMedlineWeb of Science
↵
1. Griendling KK,
2. FitzGerald GA
. Oxidative stress and cardiovascular injury: Part II: animal and human studies. Circulation 2003;108:2034-2040.
FREE Full Text
↵
1. Ushio-Fukai M,
2. Tang Y,
3. Fukai T,
4. Dikalov SI,
5. Ma Y,
6. Fujimoto M,
7. et al
. Novel role of gp91(phox)-containing NAD(P)H oxidase in vascular endothelial growth factor-induced signaling and angiogenesis. Circ Res 2002;91:1160-1167.
Abstract/FREE Full Text
↵
1. Tojo T,
2. Ushio-Fukai M,
3. Yamaoka-Tojo M,
4. Ikeda S,
5. Patrushev N,
6. Alexander RW
.Role of gp91phox (Nox2)-containing NAD(P)H oxidase in angiogenesis in response to hindlimb ischemia. Circulation 2005;111:2347-2355.
Abstract/FREE Full Text
↵
1. Chen JX,
2. Zeng H,
3. Tuo QH,
4. Yu H,
5. Meyrick B,
6. Aschner JL
. NADPH oxidase modulates myocardial Akt, ERK1/2 activation, and angiogenesis after hypoxia-reoxygenation. Am J Physiol Heart Circ Physiol 2007;292:H1664-H1674.
Abstract/FREE Full Text
↵
1. Xia C,
2. Meng Q,
3. Liu LZ,
4. Rojanasakul Y,
5. Wang XR,
6. Jiang BH
. Reactive oxygen species regulate angiogenesis and tumor growth through vascular endothelial growth factor. Cancer Res 2007;67:10823-10830.
Abstract/FREE Full Text
↵
1. Blanchetot C,
2. Boonstra J
. The ROS-NOX connection in cancer and angiogenesis.Crit Rev Eukaryot Gene Expr 2008;18:35-45.
Medline
↵
1. Xu J,
2. Wu Y,
3. Song P,
4. Zhang M,
5. Wang S,
6. Zou MH
. Proteasome-dependent degradation of guanosine 5′-triphosphate cyclohydrolase I causes tetrahydrobiopterin deficiency in diabetes mellitus. Circulation 2007;116:944-953.
Abstract/FREE Full Text
↵
1. Chen W,
2. Druhan LJ,
3. Chen CA,
4. Hemann C,
5. Chen YR,
6. Berka V,
7. et al
. Peroxynitrite induces destruction of the tetrahydrobiopterin and heme in endothelial nitric oxide synthase: transition from reversible to irreversible enzyme inhibition. Biochemistry2010;49:3129-3137.
CrossRefMedlineWeb of Science
↵
1. Milstien S,
2. Katusic Z
. Oxidation of tetrahydrobiopterin by peroxynitrite: implications for vascular endothelial function. Biochem Biophys Res Commun1999;263:681-684.
CrossRefMedlineWeb of Science
↵
1. Zou MH,
2. Shi C,
3. Cohen RA
. Oxidation of the zinc–thiolate complex and uncoupling of endothelial nitric oxide synthase by peroxynitrite. J Clin Invest2002;109:817-826.
CrossRefMedlineWeb of Science
↵
1. Laursen JB,
2. Somers M,
3. Kurz S,
4. McCann L,
5. Warnholtz A,
6. Freeman BA,
7. et al
.Endothelial regulation of vasomotion in apoE-deficient mice: implications for interactions between peroxynitrite and tetrahydrobiopterin. Circulation2001;103:1282-1288.
Abstract/FREE Full Text
↵
1. Kumar P,
2. Shen Q,
3. Pivetti CD,
4. Lee ES,
5. Wu MH,
6. Yuan SY
. Molecular mechanisms of endothelial hyperpermeability: implications in inflammation. Expert Rev Mol Med2009;11:e19.
CrossRefMedline
↵
1. Majno G
. Chronic inflammation: links with angiogenesis and wound healing. Am J Pathol 1998;153:1035-1039.
MedlineWeb of Science
↵
1. Cai H,
2. Harrison DG
. Endothelial dysfunction in cardiovascular diseases: the role of oxidant stress. Circ Res 2000;87:840-844.
Abstract/FREE Full Text
↵
1. Shen GX
. Oxidative stress and diabetic cardiovascular disorders: roles of mitochondria and NADPH oxidase. Can J Physiol Pharmacol 2010;88:241-248.
CrossRefMedline
↵
1. Bucala R,
2. Tracey KJ,
3. Cerami A
. Advanced glycosylation products quench nitric oxide and mediate defective endothelium-dependent vasodilatation in experimental diabetes. J Clin Invest 1991;87:432-438.
MedlineWeb of Science
1. Pannirselvam M,
2. Verma S,
3. Anderson TJ,
4. Triggle CR
. Cellular basis of endothelial dysfunction in small mesenteric arteries from spontaneously diabetic (db/db−/−) mice: role of decreased tetrahydrobiopterin bioavailability. Br J Pharmacol2002;136:255-263.
CrossRefMedlineWeb of Science
↵
1. Pieper GM
. Review of alterations in endothelial nitric oxide production in diabetes: protective role of arginine on endothelial dysfunction. Hypertension1998;31:1047-1060.
FREE Full Text
↵
1. Ballinger SW,
2. Patterson C,
3. Knight-Lozano CA,
4. Burow DL,
5. Conklin CA,
6. Hu Z,
7. et al
.Mitochondrial integrity and function in atherogenesis. Circulation2002;106:544-549.
Abstract/FREE Full Text
↵
1. Semenkovich CF
. Insulin resistance and atherosclerosis. J Clin Invest2006;116:1813-1822.
CrossRefMedlineWeb of Science
↵
1. Guzik TJ,
2. Mussa S,
3. Gastaldi D,
4. Sadowski J,
5. Ratnatunga C,
6. Pillai R,
7. et al
.Mechanisms of increased vascular superoxide production in human diabetes mellitus: role of NAD(P)H oxidase and endothelial nitric oxide synthase. Circulation2002;105:1656-1662.
Abstract/FREE Full Text
↵
1. Haddad P,
2. Dussault S,
3. Groleau J,
4. Turgeon J,
5. Maingrette F,
6. Rivard A
. Nox2-derived reactive oxygen species contribute to hypercholesterolemia-induced inhibition of neovascularization: effects on endothelial progenitor cells and mature endothelial cells. Atherosclerosis 2011;217:340-349.
CrossRefMedlineWeb of Science
↵
1. Judkins CP,
2. Diep H,
3. Broughton BR,
4. Mast AE,
5. Hooker EU,
6. Miller AA,
7. et al
. Direct evidence of a role for Nox2 in superoxide production, reduced nitric oxide bioavailability, and early atherosclerotic plaque formation in ApoE−/− mice. Am J Physiol Heart Circ Physiol 2010;298:H24-H32.
Abstract/FREE Full Text
↵
1. Ebrahimian TG,
2. Heymes C,
3. You D,
4. Blanc-Brude O,
5. Mees B,
6. Waeckel L,
7. et al
.NADPH oxidase-derived overproduction of reactive oxygen species impairs postischemic neovascularization in mice with type 1 diabetes. Am J Pathol2006;169:719-728.
CrossRefMedline
↵
1. Fadini GP,
2. Agostini C,
3. Sartore S,
4. Avogaro A
. Endothelial progenitor cells in the natural history of atherosclerosis. Atherosclerosis 2007;194:46-54.
CrossRefMedlineWeb of Science
↵
1. Loomans CJ,
2. de Koning EJ,
3. Staal FJ,
4. Rookmaaker MB,
5. Verseyden C,
6. de Boer HC,
7. et al
. Endothelial progenitor cell dysfunction: a novel concept in the pathogenesis of vascular complications of type 1 diabetes. Diabetes 2004;53:195-199.
Abstract/FREE Full Text
↵
1. Aktunc E,
2. Ozacmak VH,
3. Ozacmak HS,
4. Barut F,
5. Buyukates M,
6. Kandemir O,
7. et al
.N-acetyl cysteine promotes angiogenesis and clearance of free oxygen radicals, thus improving wound healing in an alloxan-induced diabetic mouse model of incisional wound. Clin Exp Dermatol 2010;35:902-909.
CrossRefMedline
↵
1. Oyama Y,
2. Kawasaki H,
3. Hattori Y,
4. Kanno M
. Attenuation of endothelium-dependent relaxation in aorta from diabetic rats. Eur J Pharmacol1986;132:75-78.
CrossRefMedlineWeb of Science
↵
1. Alexander RW
. Theodore Cooper Memorial Lecture. Hypertension and the pathogenesis of atherosclerosis. Oxidative stress and the mediation of arterial inflammatory response: a new perspective. Hypertension 1995;25:155-161.
Abstract/FREE Full Text
↵
1. Abaci A,
2. Oguzhan A,
3. Kahraman S,
4. Eryol NK,
5. Unal S,
6. Arinc H,
7. et al
. Effect of diabetes mellitus on formation of coronary collateral vessels. Circulation1999;99:2239-2242.
Abstract/FREE Full Text
↵
1. Kim HW,
2. Lin A,
3. Guldberg RE,
4. Ushio-Fukai M,
5. Fukai T
. Essential role of extracellular SOD in reparative neovascularization induced by hindlimb ischemia.Circ Res 2007;101:409-419.
Abstract/FREE Full Text
↵
1. Lundberg JO,
2. Weitzberg E,
3. Gladwin MT
. The nitrate–nitrite–nitric oxide pathway in physiology and therapeutics. Nat Rev Drug Discov 2008;7:156-167.
CrossRefMedlineWeb of Science
↵
1. Dudzinski DM,
2. Michel T
. Life history of eNOS: partners and pathways.Cardiovasc Res 2007;75:247-260.
Abstract/FREE Full Text
1. Mount PF,
2. Kemp BE,
3. Power DA
. Regulation of endothelial and myocardial NO synthesis by multi-site eNOS phosphorylation. J Mol Cell Cardiol 2007;42:271-279.
CrossRefMedlineWeb of Science
↵
1. Fleming I,
2. Busse R
. Signal transduction of eNOS activation. Cardiovasc Res1999;43:532-541.
Abstract/FREE Full Text
↵
1. Fulton D,
2. Gratton JP,
3. McCabe TJ,
4. Fontana J,
5. Fujio Y,
6. Walsh K,
7. et al
. Regulation of endothelium-derived nitric oxide production by the protein kinase Akt. Nature1999;399:597-601.
CrossRefMedline
↵
1. Gonzalez E,
2. Kou R,
3. Lin AJ,
4. Golan DE,
5. Michel T
. Subcellular targeting and agonist-induced site-specific phosphorylation of endothelial nitric-oxide synthase. J Biol Chem 2002;277:39554-39560.
Abstract/FREE Full Text
↵
1. Michell BJ,
2. Harris MB,
3. Chen ZP,
4. Ju H,
5. Venema VJ,
6. Blackstone MA,
7. et al
.Identification of regulatory sites of phosphorylation of the bovine endothelial nitric-oxide synthase at serine 617 and serine 635. J Biol Chem2002;277:42344-42351.
Abstract/FREE Full Text
↵
1. Boo YC,
2. Sorescu G,
3. Boyd N,
4. Shiojima I,
5. Walsh K,
6. Du J,
7. et al
. Shear stress stimulates phosphorylation of endothelial nitric-oxide synthase at Ser1179 by Akt-independent mechanisms: role of protein kinase A. J Biol Chem2002;277:3388-3396.
Abstract/FREE Full Text
1. Boo YC
. Shear stress stimulates phosphorylation of protein kinase A substrate proteins including endothelial nitric oxide synthase in endothelial cells. Exp Mol Med2006;38:453.
MedlineWeb of Science
↵
1. Boo YC,
2. Hwang J,
3. Sykes M,
4. Michell BJ,
5. Kemp BE,
6. Lum H,
7. et al
. Shear stress stimulates phosphorylation of eNOS at Ser(635) by a protein kinase A-dependent mechanism. Am J Physiol Heart Circ Physiol 2002;283:H1819-H1828.
Abstract/FREE Full Text
↵
1. Murohara T,
2. Horowitz JR,
3. Silver M,
4. Tsurumi Y,
5. Chen D,
6. Sullivan A,
7. et al
.Vascular endothelial growth factor/vascular permeability factor enhances vascular permeability via nitric oxide and prostacyclin. Circulation 1998;97:99-107.
Abstract/FREE Full Text
↵
1. Namkoong S,
2. Lee SJ,
3. Kim CK,
4. Kim YM,
5. Chung HT,
6. Lee H,
7. et al
. Prostaglandin E2 stimulates angiogenesis by activating the nitric oxide/cGMP pathway in human umbilical vein endothelial cells. Exp Mol Med 2005;37:588-600.
MedlineWeb of Science
↵
1. Zheng S,
2. Li W,
3. Xu M,
4. Bai X,
5. Zhou Z,
6. Han J,
7. et al
. Calcitonin gene-related peptide promotes angiogenesis via AMP-activated protein kinase. Am J Physiol Cell Physiol 2010;299:C1485-C1492.
Abstract/FREE Full Text
↵
1. Hashimoto A,
2. Miyakoda G,
3. Hirose Y,
4. Mori T
. Activation of endothelial nitric oxide synthase by cilostazol via a cAMP/protein kinase A- and phosphatidylinositol 3-kinase/Akt-dependent mechanism. Atherosclerosis 2006;189:350-357.
CrossRefMedlineWeb of Science
↵
1. Bae SW,
2. Kim HS,
3. Cha YN,
4. Park YS,
5. Jo SA,
6. Jo I
. Rapid increase in endothelial nitric oxide production by bradykinin is mediated by protein kinase A signaling pathway. Biochem Biophys Res Commun 2003;306:981-987.
CrossRefMedlineWeb of Science
↵
1. Silvestre JS,
2. Bergaya S,
3. Tamarat R,
4. Duriez M,
5. Boulanger CM,
6. Levy BI
.Proangiogenic effect of angiotensin-converting enzyme inhibition is mediated by the bradykinin B(2) receptor pathway. Circ Res 2001;89:678-683.
Abstract/FREE Full Text
↵
1. Ray CJ,
2. Marshall JM
. The cellular mechanisms by which adenosine evokes release of nitric oxide from rat aortic endothelium. J Physiol 2006;570:85-96.
Abstract/FREE Full Text
↵
1. Lu Y,
2. Xiong Y,
3. Huo Y,
4. Han J,
5. Yang X,
6. Zhang R,
7. et al
. Grb-2-associated binder 1 (Gab1) regulates postnatal ischemic and VEGF-induced angiogenesis through the protein kinase A-endothelial NOS pathway. Proc Natl Acad Sci USA2011;108:2957-2962.
Abstract/FREE Full Text
↵
1. Namkoong S,
2. Kim CK,
3. Cho YL,
4. Kim JH,
5. Lee H,
6. Ha KS,
7. et al
. Forskolin increases angiogenesis through the coordinated cross-talk of PKA-dependent VEGF expression and Epac-mediated PI3K/Akt/eNOS signaling. Cell Signal2009;21:906-915.
CrossRefMedlineWeb of Science
↵
1. Mees B,
2. Wagner S,
3. Ninci E,
4. Tribulova S,
5. Martin S,
6. van Haperen R,
7. et al
.Endothelial nitric oxide synthase activity is essential for vasodilation during blood flow recovery but not for arteriogenesis. Arterioscler Thromb Vasc Biol2007;27:1926-1933.
Abstract/FREE Full Text
↵
1. Venkatesh PK,
2. Pattillo CB,
3. Branch B,
4. Hood J,
5. Thoma S,
6. Illum S,
7. et al
.Dipyridamole enhances ischaemia-induced arteriogenesis through an endocrine nitrite/nitric oxide-dependent pathway. Cardiovasc Res 2010;85:661-670.
Abstract/FREE Full Text
↵
1. Hiasa K,
2. Ishibashi M,
3. Ohtani K,
4. Inoue S,
5. Zhao Q,
6. Kitamoto S,
7. et al
. Gene transfer of stromal cell-derived factor-1alpha enhances ischemic vasculogenesis and angiogenesis via vascular endothelial growth factor/endothelial nitric oxide synthase-related pathway: next-generation chemokine therapy for therapeutic neovascularization. Circulation 2004;109:2454-2461.
Abstract/FREE Full Text
↵
1. Lee DH,
2. Lee HR,
3. Shin HK,
4. Park SY,
5. Hong KW,
6. Kim EK,
7. et al
. Cilostazol enhances integrin-dependent homing of progenitor cells by activation of cAMP-dependent protein kinase in synergy with Epac1. J Neurosci Res 2011;89:650-660.
CrossRefMedline
↵
1. Yamamizu K,
2. Kawasaki K,
3. Katayama S,
4. Watabe T,
5. Yamashita JK
. Enhancement of vascular progenitor potential by protein kinase A through dual induction of Flk-1 and Neuropilin-1. Blood 2009;114:3707-3716.
Abstract/FREE Full Text
↵
1. Thacher TN,
2. Silacci P,
3. Stergiopulos N,
4. da Silva RF
. Autonomous effects of shear stress and cyclic circumferential stretch regarding endothelial dysfunction and oxidative stress: an ex vivo arterial model. J Vasc Res 2010;47:336-345.
CrossRefMedline
↵
1. Ziegler T,
2. Silacci P,
3. Harrison VJ,
4. Hayoz D
. Nitric oxide synthase expression in endothelial cells exposed to mechanical forces. Hypertension 1998;32:351-355.
Abstract/FREE Full Text
↵
1. Takeda H,
2. Komori K,
3. Nishikimi N,
4. Nimura Y,
5. Sokabe M,
6. Naruse K
. Bi-phasic activation of eNOS in response to uni-axial cyclic stretch is mediated by differential mechanisms in BAECs. Life Sci 2006;79:233-239.
CrossRefMedlineWeb of Science
↵
1. Kolluru GK,
2. Sinha S,
3. Majumder S,
4. Muley A,
5. Siamwala JH,
6. Gupta R,
7. et al
. Shear stress promotes nitric oxide production in endothelial cells by sub-cellular delocalization of eNOS: a basis for shear stress mediated angiogenesis. Nitric Oxide2010;22:304-315.
CrossRefMedlineWeb of Science
↵
1. Kovac A,
2. Erickson MA,
3. Banks WA
. Brain microvascular pericytes are immunoactive in culture: cytokine, chemokine, nitric oxide, and LRP-1 expression in response to lipopolysaccharide. J Neuroinflammation 2011;8:139.
CrossRefMedline
↵
1. Martin AR,
2. Bailie JR,
3. Robson T,
4. McKeown SR,
5. Al-Assar O,
6. McFarland A,
7. et al
.Retinal pericytes control expression of nitric oxide synthase and endothelin-1 in microvascular endothelial cells. Microvasc Res 2000;59:131-139.
CrossRefMedlineWeb of Science
↵
1. Tortora G,
2. Caputo R,
3. Damiano V,
4. Bianco R,
5. Fontanini G,
6. Cuccato S,
7. et al
.Combined blockade of protein kinase A and bcl-2 by antisense strategy induces apoptosis and inhibits tumor growth and angiogenesis. Clin Cancer Res2001;7:2537-2544.
Abstract/FREE Full Text
↵
1. Tortora G,
2. Ciardiello F
. Protein kinase A as target for novel integrated strategies of cancer therapy. Ann N Y Acad Sci 2002;968:139-147.
MedlineWeb of Science
↵
1. Fiorio Pla A,
2. Genova T,
3. Pupo E,
4. Tomatis C,
5. Genazzani A,
6. Zaninetti R,
7. et al
.Multiple roles of protein kinase a in arachidonic acid-mediated Ca²⁺ entry and tumor-derived human endothelial cell migration. Mol Cancer Res2010;8:1466-1476.
Abstract/FREE Full Text
↵
1. Heijnen HF,
2. Waaijenborg S,
3. Crapo JD,
4. Bowler RP,
5. Akkerman JW,
6. Slot JW
.Colocalization of eNOS and the catalytic subunit of PKA in endothelial cell junctions: a clue for regulated NO production. J Histochem Cytochem 2004;52:1277-1285.
Abstract/FREE Full Text
↵
1. Cheng X,
2. Ji Z,
3. Tsalkova T,
4. Mei F
. Epac and PKA: a tale of two intracellular cAMP receptors. Acta Biochim Biophys Sin (Shanghai) 2008;40:651-662.
Abstract/FREE Full Text
↵
1. Ignarro LJ
. Nitric oxide as a unique signaling molecule in the vascular system: a historical overview. J Physiol Pharmacol 2002;53:503-514.
MedlineWeb of Science
↵
1. Garg UC,
2. Hassid A
. Nitric oxide-generating vasodilators and 8-bromo-cyclic guanosine monophosphate inhibit mitogenesis and proliferation of cultured rat vascular smooth muscle cells. J Clin Invest 1989;83:1774-1777.
MedlineWeb of Science
↵
1. Zheng H,
2. Dai T,
3. Zhou B,
4. Zhu J,
5. Huang H,
6. Wang M,
7. et al
. SDF-1alpha/CXCR4 decreases endothelial progenitor cells apoptosis under serum deprivation by PI3K/Akt/eNOS pathway. Atherosclerosis 2008;201:36-42.
CrossRefMedlineWeb of Science
↵
1. Liu ZJ,
2. Velazquez OC
. Hyperoxia, endothelial progenitor cell mobilization, and diabetic wound healing. Antioxid Redox Signal 2008;10:1869-1882.
CrossRefMedlineWeb of Science
↵
1. Kevil CG,
2. Kolluru GK,
3. Pattillo CB,
4. Giordano T
. Inorganic nitrite therapy: historical perspective and future directions. Free Radic Biol Med 2011;51:576-593.
CrossRefMedline
↵
1. Duncan C,
2. Dougall H,
3. Johnston P,
4. Green S,
5. Brogan R,
6. Leifert C,
7. et al
. Chemical generation of nitric oxide in the mouth from the enterosalivary circulation of dietary nitrate. Nat Med 1995;1:546-551.
CrossRefMedlineWeb of Science
↵
1. Lundberg JO,
2. Govoni M
. Inorganic nitrate is a possible source for systemic generation of nitric oxide. Free Radic Biol Med 2004;37:395-400.
CrossRefMedlineWeb of Science
↵
1. Kumar D,
2. Branch BG,
3. Pattillo CB,
4. Hood J,
5. Thoma S,
6. Simpson S,
7. et al
. Chronic sodium nitrite therapy augments ischemia-induced angiogenesis and arteriogenesis. Proc Natl Acad Sci USA 2008;105:7540-7545.
Abstract/FREE Full Text
↵
1. Li J,
2. Fenton RA,
3. Wheeler HB,
4. Powell CC,
5. Peyton BD,
6. Cutler BS,
7. et al
. Adenosine A2a receptors increase arterial endothelial cell nitric oxide. J Surg Res1998;80:357-364.
CrossRefMedlineWeb of Science
↵
1. Xu Z,
2. Park SS,
3. Mueller RA,
4. Bagnell RC,
5. Patterson C,
6. Boysen PG
. Adenosine produces nitric oxide and prevents mitochondrial oxidant damage in rat cardiomyocytes. Cardiovasc Res 2005;65:803-812.
Abstract/FREE Full Text
↵
1. Elrod JW,
2. Calvert JW,
3. Gundewar S,
4. Bryan NS,
5. Lefer DJ
. Nitric oxide promotes distant organ protection: evidence for an endocrine role of nitric oxide. Proc Natl Acad Sci USA 2008;105:11430-11435.
Abstract/FREE Full Text
↵
1. Duranski MR,
2. Greer JJ,
3. Dejam A,
4. Jaganmohan S,
5. Hogg N,
6. Langston W,
7. et al
.Cytoprotective effects of nitrite during in vivo ischemia–reperfusion of the heart and liver. J Clin Invest 2005;115:1232-1240.
CrossRefMedlineWeb of Science
↵
1. Lorenowicz MJ,
2. Fernandez-Borja M,
3. Kooistra MR,
4. Bos JL,
5. Hordijk PL
. PKA and Epac1 regulate endothelial integrity and migration through parallel and independent pathways. Eur J Cell Biol 2008;87:779-792.
CrossRefMedlineWeb of Science
↵
1. Torella D,
2. Gasparri C,
3. Ellison GM,
4. Curcio A,
5. Leone A,
6. Vicinanza C,
7. et al
.Differential regulation of vascular smooth muscle and endothelial cell proliferation in vitro and in vivo by cAMP/PKA-activated p85alphaPI3K. Am J Physiol Heart Circ Physiol 2009;297:H2015-H2025.
Abstract/FREE Full Text
↵
1. Michell BJ,
2. Chen Z,
3. Tiganis T,
4. Stapleton D,
5. Katsis F,
6. Power DA,
7. et al
.Coordinated control of endothelial nitric-oxide synthase phosphorylation by protein kinase C and the cAMP-dependent protein kinase. J Biol Chem2001;276:17625-17628.
Abstract/FREE Full Text
↵
1. Hurley RL,
2. Barre LK,
3. Wood SD,
4. Anderson KA,
5. Kemp BE,
6. Means AR,
7. et al
.Regulation of AMP-activated protein kinase by multisite phosphorylation in response to agents that elevate cellular cAMP. J Biol Chem 2006;281:36662-36672.
Abstract/FREE Full Text
↵
1. Thors B,
2. Halldorsson H,
3. Thorgeirsson G
. Thrombin and histamine stimulate endothelial nitric-oxide synthase phosphorylation at Ser1177 via an AMPK mediated pathway independent of PI3K-Akt. FEBS Lett 2004;573:175-180.
CrossRefMedlineWeb of Science
↵
1. Kureishi Y,
2. Luo Z,
3. Shiojima I,
4. Bialik A,
5. Fulton D,
6. Lefer DJ,
7. et al
. The HMG-CoA reductase inhibitor simvastatin activates the protein kinase Akt and promotes angiogenesis in normocholesterolemic animals. Nat Med 2000;6:1004-1010.
CrossRefMedlineWeb of Science
↵
1. Brouet A,
2. Sonveaux P,
3. Dessy C,
4. Moniotte S,
5. Balligand JL,
6. Feron O
. Hsp90 and caveolin are key targets for the proangiogenic nitric oxide-mediated effects of statins. Circ Res 2001;89:866-873.
Abstract/FREE Full Text
↵
1. Harris MB,
2. Blackstone MA,
3. Sood SG,
4. Li C,
5. Goolsby JM,
6. Venema VJ,
7. et al
. Acute activation and phosphorylation of endothelial nitric oxide synthase by HMG-CoA reductase inhibitors. Am J Physiol Heart Circ Physiol 2004;287:H560-H566.
Abstract/FREE Full Text
↵
1. Kalinowski L,
2. Dobrucki LW,
3. Brovkovych V,
4. Malinski T
. Increased nitric oxide bioavailability in endothelial cells contributes to the pleiotropic effect of cerivastatin.Circulation 2002;105:933-938.
Abstract/FREE Full Text
↵
1. Laufs U,
2. La Fata V,
3. Plutzky J,
4. Liao JK
. Upregulation of endothelial nitric oxide synthase by HMG CoA reductase inhibitors. Circulation 1998;97:1129-1135.
Abstract/FREE Full Text
↵
1. Landmesser U,
2. Engberding N,
3. Bahlmann FH,
4. Schaefer A,
5. Wiencke A,
6. Heineke A,
7. et al
. Statin-induced improvement of endothelial progenitor cell mobilization, myocardial neovascularization, left ventricular function, and survival after experimental myocardial infarction requires endothelial nitric oxide synthase.Circulation 2004;110:1933-1939.
Abstract/FREE Full Text
↵
1. Pattillo CB,
2. Bir SC,
3. Branch BG,
4. Greber E,
5. Shen X,
6. Pardue S,
7. et al
. Dipyridamole reverses peripheral ischemia and induces angiogenesis in the Db/Db diabetic mouse hind-limb model by decreasing oxidative stress. Free Radic Biol Med2011;50:262-269.
CrossRefMedline
↵
1. Kawasaki K,
2. Smith RS Jr.,
3. Hsieh CM,
4. Sun J,
5. Chao J,
6. Liao JK
. Activation of the phosphatidylinositol 3-kinase/protein kinase Akt pathway mediates nitric oxide-induced endothelial cell migration and angiogenesis. Mol Cell Biol2003;23:5726-5737.
Abstract/FREE Full Text
↵
1. Budovskaya YV,
2. Stephan JS,
3. Deminoff SJ,
4. Herman PK
. An evolutionary proteomics approach identifies substrates of the cAMP-dependent protein kinase.Proc Natl Acad Sci USA 2005;102:13933-13938.
Abstract/FREE Full Text
↵
1. Gao X,
2. Jin C,
3. Ren J,
4. Yao X,
5. Xue Y
. Proteome-wide prediction of PKA phosphorylation sites in eukaryotic kingdom. Genomics 2008;92:457-463.
CrossRefMedlineWeb of Science

上一篇： 动脉粥样硬化中平滑肌细胞表型转换

下一篇： 通过定位于跨膜蛋白在体内对胰腺β细胞进行多模态成像

学科代码：内科学　　　关键词：PKA eNOS Nitric oxide Nitrite Vascular remodelling
来源： Cardiovascular Research

顶一下（0）

您可能感兴趣的文章

发表评论网友评论(0)

发表评论

登录后方可发表评论，点击此处登录

PKA/eNOS通路在缺血性组织疾病治疗性血管再生中的作用

Abstract

Key words

1. Introduction

2. Neovascularization and NO bioavailability

2.1 Angiogenesis and NO bioavailability

2.2 Vasculogenesis and NO bioavailability

2.3 Arteriogenesis and NO bioavailability

3. Relationship of NO and ROS, and their effects on neovascularization

4. ROS, diabetes, and atherosclerosis

5. Signalling pathways leading to NO generation during ischaemic neovascularization

5.1 Activation of the PKA/eNOS signalling pathway

5.2 PKA/eNOS signalling pathway in neovascularization

5.3 Cellular basis of PKA/eNOS-mediated neovascularization

5.4 NO/nitrite/nitrate system

5.5 Signalling interactions between PKA/eNOS and other angiogenic pathways

6. Different therapies that potentiate the PKA/eNOS and nitrite/NO system

6.1 Statins

6.2 Dipyridamole

7. Perspectives and conclusions

Funding

Footnotes

References

可能感兴趣的

新版网站上线，新特性介绍

中国选择达标看我

爱唯医学社区上线！sns.elseviermed.cn

同类期刊影响因子排行

投稿指南

中国作者成功投稿经验访谈

投稿交流

PKA/eNOS通路在缺血性组织疾病治疗性血管再生中的作用

Abstract

Key words

1. Introduction

2. Neovascularization and NO bioavailability

2.1 Angiogenesis and NO bioavailability

2.2 Vasculogenesis and NO bioavailability

2.3 Arteriogenesis and NO bioavailability

3. Relationship of NO and ROS, and their effects on neovascularization

4. ROS, diabetes, and atherosclerosis

5. Signalling pathways leading to NO generation during ischaemic neovascularization

5.1 Activation of the PKA/eNOS signalling pathway

5.2 PKA/eNOS signalling pathway in neovascularization

5.3 Cellular basis of PKA/eNOS-mediated neovascularization

5.4 NO/nitrite/nitrate system

5.5 Signalling interactions between PKA/eNOS and other angiogenic pathways

6. Different therapies that potentiate the PKA/eNOS and nitrite/NO system

6.1 Statins

6.2 Dipyridamole

7. Perspectives and conclusions

Funding

Footnotes

References

可能感兴趣的

新版网站上线，新特性介绍

中国选择 达标看我

爱唯医学社区上线！sns.elseviermed.cn

同类期刊影响因子排行

投稿指南

中国作者成功投稿经验访谈

投稿交流

中国选择达标看我